81 related articles for article (PubMed ID: 9757198)
1. [Results of clinical study with epirubicin hydrochloride injectable solution and cyclophosphamide in breast cancer].
Koyama H; Adachi I; Tajima T; Kanda K; Yoshida M; Miura S; Nakao K; Kikkawa N; Takai S; Toge T; Tamura K; Inaji H; Shiba E
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1721-9. PubMed ID: 9757198
[TBL] [Abstract][Full Text] [Related]
2. [Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Kotake T; Koyanagi T; Akaza H; Shimazaki J; Ito H; Hosaka M; Okajima E; Saito Y; Miyanaga N; Kuroda M; Hirao Y
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1189-95. PubMed ID: 9679582
[TBL] [Abstract][Full Text] [Related]
3. [Results of clinical study with epirubicin hydrochloride injectable solution in hepatoma].
Monden M; Nakamura H; Yayoi E; Monden T; Ohi H; Arisawa J; Masuzawa M; Shimizu T; Tomono N; Seki K; Nakao N; Todo A; Inoue Y; Sakon M; Ohsaki Y; Hosoki T
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1713-9. PubMed ID: 9757197
[TBL] [Abstract][Full Text] [Related]
4. [Phase II study of epirubicin on breast cancer: a cooperative group study].
Tominaga T; Kitamura M; Nomura Y; Abe O; Enomoto K; Ikeda T; Izuo M; Iino Y; Taguchi T; Tamura K
Gan To Kagaku Ryoho; 1986 Jun; 13(6):2187-92. PubMed ID: 3459397
[TBL] [Abstract][Full Text] [Related]
5. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
Wada N; Kobayashi H; Oka S; Ando J; Tamura H
Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
[TBL] [Abstract][Full Text] [Related]
6. [Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
Tashiro H; Takahashi I; Yamamura S; Ishikawa T; Yanaga K; Wakasugi K; Matsusaka T; Kume K
Gan To Kagaku Ryoho; 1999 May; 26(6):775-9. PubMed ID: 10410146
[TBL] [Abstract][Full Text] [Related]
7. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
9. [Weekly administration of paclitaxel and pirarubicine for recurrent breast cancer].
Shimizu T; Iwasa T; Koike S; Nakamura T; Kanai T; Komatsu D
Gan To Kagaku Ryoho; 2003 Jan; 30(1):105-9. PubMed ID: 12557713
[TBL] [Abstract][Full Text] [Related]
10. Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide.
Papaldo P; Lopez M; Marolla P; Cortesi E; Antimi M; Terzoli E; Vici P; Barone C; Ferretti G; Di Cosimo S; Carlini P; Nisticò C; Conti F; Di Lauro L; Botti C; Di Filippo F; Fabi A; Giannarelli D; Calabresi F
J Clin Oncol; 2005 Oct; 23(28):6908-18. PubMed ID: 16129844
[TBL] [Abstract][Full Text] [Related]
11. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
12. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
[TBL] [Abstract][Full Text] [Related]
13. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
[TBL] [Abstract][Full Text] [Related]
14. High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.
Cottu PH; Extra JM; Espie M; Marolleau JP; de Roquancourt A; Makke J; Miclea JM; Laurence V; Mayeur D; Lerebours F; Cuvier C; Marty M
Br J Cancer; 2001 Nov; 85(9):1240-6. PubMed ID: 11720455
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of two different regimens as neoadjuvant chemotherapy for breast cancer].
Yang D; Tong F; Cao Y; Liu P; Zhou B; Liu H; Qiao X; Zhang J
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):303-5. PubMed ID: 12515634
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of effects from neoadjuvant chemotherapy with epirubicin plus paclitaxel in cases of locally advanced breast cancer--comparative study of treatment with 2 and 4 cycles].
Tong F; Yang D; Zhou B; Cao Y; Liu P; Liu H; Wang S; Qiao X; Zhang J
Gan To Kagaku Ryoho; 2004 Feb; 31(2):205-8. PubMed ID: 14997752
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.
Unsal M; Erturk D
Saudi Med J; 2003 Jun; 24(6):628-31. PubMed ID: 12847592
[TBL] [Abstract][Full Text] [Related]
18. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
Miyauchi M; Yamamoto N; Nakajima N; Suzuki M; Takahashi M; Ohno K; Ogawa K; Tsukamoto T; Yamamoto K; Oheda Y;
Gan To Kagaku Ryoho; 2001 Jan; 28(1):43-8. PubMed ID: 11201379
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant chemotherapy with docetaxel plus epirubicin for locally advanced breast cancer: a multi-center phase II study].
Shen ZZ; Liu GY; Su FX; He PQ; Yang MT; Shi JY; Sheng Y; Zou Q; Li YF
Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):126-8. PubMed ID: 15946557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
